Jaguar Health, Inc. (JAGX) is a leading biopharmaceutical company mainly focused on developing innovative, plant-derived, and non-opioid therapeutics for people and animals with GI distress such as chronic, debilitating diarrhea. The company, through its subsidiary, develops and commercializes plant-derived human gastrointestinal therapeutics from plants harvested from rainforests. It commercializes Mytesi which is a Crofelemer used for various cancer related and bowel-related treatments
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The price of JAGX stock during the regular trading of December 21, 2021, with a significant rise of 20% was $1.38. At last check in the aftermarket, the price decreased by 4.35%.
Events and Happenings
On December 21, 2021, JAGX reported that it received restricted approval from FDA to commercialize Canalevia-CA1, Jaguar’s oral plant-based prescription drug for the cure of chemotherapy-induced diarrhea (CID) in dogs. This is the pioneer product to receive any type of endorsement from the FDA for the treatment of CID in dogs.
On December 13, 2021, JAGX reported that the European Commission had accepted the decision to give Orphan Drug Designation (ODD) to crofelemer for the treatment of short bowel syndrome (SBS) in the EU. On December 10, 2021, JAGX presented that third-party results from the HALT-D trial assessing crofelemer for the prevention of CID in HER2-positive breast cancer patients medicated with trastuzumab, pertuzumab, and a taxane. These treatments caused CID in almost 80% of patients with breast cancer, and reached class 3 in 8-12% of patients.
On December 6, 2021, JAGX reported that it hosted an event on December 9, regarding discussions with top-notch oncologists on the devastating impact of diarrhea because of cancer and cancer therapy. The event also included presentations by the management of the company on its OnTarget Pivotal Phase 3 trials.
On November 17, 2021, JAGX announced its third-quarter 2021 financial results. The quarter ended on September 30, 2021. Some of the key highlights are as follows
Net Product Revenue
Net product revenue generated by the company during Q3 2021 was $0.63 million as compared to the same period of 2020 when it was $2.7 million. The net revenue decreased over the period of the year
Net Loss per Share
The company reported a basic and diluted net loss per share of $12 million or $0.27 per share for Q3 2021 as opposed to the same period prior year when it was $8.2 million or $0.62 per share. The net loss decreased over the year period.
The price of JAGX stock is up 18% from the past week primarily because of the permission of commercialization given by the FDA. While in the aftermarket the stock declined considerably due to uncertain reasons. The analysts are hoping that the company will once again be on the track of attracting potential investors after the groundbreaking collaborations and announcements.